Myriad Genetics (MYGN) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Myriad Genetics (MYGN) PT Raised to $23 at Jefferies
August 9, 2017 8:40 AM EDTJefferies raised its price target on Myriad Genetics (NASDAQ: MYGN) to $23.00 (from $21.00) while maintaining a Hold rating. MYGN's initial FY18 revenue outlook fell ~$30M below consensus, owing to ASP headwinds it will absorb in hereditary cancer from steps taken to secure LT, fixed-price... More
